

IMSUT Hospital

Department of Joint Surgery

関節外科

| Project Professor Minoru Tanaka, M.D., Ph.D.

| 特任教授 博士(医学) 田中 実

The Department of Joint Surgery was established in 2006 to evaluate and treat hemophilic arthropathy. We have provided specialized care to hemophilia patients across Japan for nearly two decades, addressing their unique orthopedic needs. Our services have included comprehensive joint evaluations, surgical interventions such as joint arthroplasties and arthroscopic synovectomies, and pioneering research in perioperative bleeding control and the pathogenesis of hemophilic arthropathy. In collaboration with the Department of Orthopedic Surgery at the University of Tokyo, we have also contributed to the development of innovative therapies, including mesenchymal stem cell treatments for hemophilic arthropathy. Over the years, more than 270 surgical procedures have been performed, including those addressing complex cases involving coagulation disorders such as factor VII deficiency and Von Willebrand disease.

New Organizational Structure in 2024

The Department of Joint Surgery has transitioned to a new organizational structure. While maintaining our commitment to hemophilia outpatient care, the department has shifted its focus towards tumor rehabilitation in collaboration with the Rehabilitation Department at the University of Tokyo Hospital. This collaboration has strengthened comprehensive rehabilitation services, including cancer rehabilitation. Through this partnership, we have enhanced our ability to deliver high-quality care to a diverse patient population. Despite a limited number of occupational therapists (OT) and physical therapists (PT), we remain dedicated to providing the highest standard of care. By maintaining close collaboration with nursing

staff, we ensure that our patients receive the support they need as part of a coordinated team effort.

Future Directions

The Department of Joint Surgery aims to enhance its rehabilitation services further while continuing to uphold its legacy of excellence in hemophilic arthropathy care. Currently, we support a diverse patient population, including those recovering from hematologic and neurosurgical conditions. Moving forward, we will continue to explore new opportunities for research and collaboration, ensuring that our patients receive cutting-edge treatments and therapies. We remain dedicated to doing our best for our patients and improving their quality of life.